Home › Skin Cancer › NCT07213154
Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions
Assessment of Novel Label-free Optical Imaging Technology for the Evaluation of Skin Lesions
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Male or Female * Candidate with skin lesions * Signed study-specific informed consent prior to study entry * ≥ 18 years old Exclusion Criteria: * Prior surgery or radiotherapy to the area to be treated
About the study
This clinical trial studies how well an optical imaging scan called quantitative oblique back-illumination microscopy (qOBM) helps in diagnosing skin cancer in patients with skin lesions. qOBM is a non-invasive procedure that uses red light for illumination, and may work better than no imaging procedures in aiding doctors in diagnosing skin lesions.
What is being tested
- Quantitative Oblique Back-Illumination Microscopy (procedure)
- Radiation Therapy (radiation)
Sponsor: Emory University · Participants: 10 · Started: Oct 15, 2025
Contact the study team
- Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR · Phone: 404-778-3473
Official record on ClinicalTrials.gov — NCT07213154
Locations in the U.S.
| Georgia | Emory University Hospital Midtown, Atlanta Emory University Hospital/Winship Cancer Institute, Atlanta |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.